Article Text

Download PDFPDF
CBD products that resemble tobacco products enter traditional retail outlets
  1. Doris G Gammon,
  2. Jennifer Gaber,
  3. Youn O Lee
  1. Center for Health Policy Science and Tobacco Research, RTI International, Research Triangle Park, North Carolina, USA
  1. Correspondence to Dr Youn O Lee, RTI International, Research Triangle Park, NC 27709, USA; younlee{at}rti.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Introduction

The US Food and Drug Administration issued a final rule in 2016 deeming new tobacco products (any product made or derived from tobacco that is intended for human consumption, including any component, part or accessory of a tobacco product) under its authority. The products include electronic nicotine delivery systems, also referred to as vapes, vaporisers or electronic cigarettes, and products meeting the statutory definition that may be developed in the future.1 The US Agriculture Improvement Act of 20182 (known as the Farm Bill) removed hemp from the definition of marijuana in the Controlled Substance Act, effectively legalising cannabis-derived products with delta-9-tetrahydrocannabinol (THC) concentrations of no more than 0.3%. In contrast to high-THC cannabis products legally sold in some states, products primarily featuring cannabidiol (CBD) are now widely available in many forms nationally, including vaping liquids for use in vaping devices.3 4

Despite the availability of CBD products consumed with vaping devices, there is little research …

View Full Text

Footnotes

  • Contributors DG conceptualised the study and drafted the manuscript. JG conducted data analysis and contributed to the manuscript. YL contributed to conceptualisation and drafting of the manuscript.

  • Funding This study was funded by RTI International.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data may be obtained from a third party and are not publicly available.